Psyched Wellness moves a step closer to commencing its Phase I clinical trial on AME-1. The company is still targeting commercialization for 2022.
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
The DEA fights to keep psychedelic drugs illegal while it admits these drugs have valuable medical uses. Meanwhile, Americans are dying every day from lack of legal access.
MINDCURE reports a net loss for the fiscal year of CAD$10.2 million as it prepares to deploy its iSTRYM digital therapeutics platform. Cash and equivalents of CAD$18.3 million.
After our July interview with CEO Kelsey Ramsden about the company’s Ibogaine synthesis, August brought more exciting announcements for Mind Cure Health Inc.
Red Light Holland reports its Q1 for fiscal year 2022. The company also confirms closing on its acquisition of Mera Life Sciences.
A new double-blind, placebo-controlled neuroimaging study sheds light on how psilocybin alters the way in which the brain processes tactile sensations and mental representations of one’s body.
As investors look to fine-tune their portfolios after the summer, we review the psychedelic drug industry and public company performance in 2021.